Weber M A, Drayer J I, Priest R T, Chen T C
Am J Nephrol. 1982;2(1):6-11. doi: 10.1159/000166575.
The acute blood pressure response to the angiotensin converting enzyme inhibitor, captopril, was used to measure participation of the renin-angiotensin system in treatment-resistant hypertension. By 2 h after a single 25-mg oral captopril dose in patients still receiving a diuretic-vasodilator-beta-blocker combination, systolic and diastolic blood pressures had fallen significantly; the decrease in diastolic pressure correlated with the control (immediately pre-captopril) plasma renin activity (r = 0.64, p less than 0.001). Apart from its possible contribution to the underlying hypertension, this captopril-identified renin component may have reflected diuretic and vasodilator-induced renin stimulation that could not adequately be prevented by the renin-lowering properties of the beta-blocker. Captopril, and perhaps other specific antirenin drugs, therefore, may be valuable adjuncts to treatment in patients with hypertension refractory to conventional therapy.
使用血管紧张素转换酶抑制剂卡托普利的急性血压反应来衡量肾素-血管紧张素系统在难治性高血压治疗中的参与情况。在仍接受利尿剂-血管扩张剂-β受体阻滞剂联合治疗的患者中,单次口服25毫克卡托普利后2小时,收缩压和舒张压显著下降;舒张压的下降与对照(卡托普利给药前即刻)血浆肾素活性相关(r = 0.64,p < 0.001)。除了其可能对潜在高血压的作用外,这种由卡托普利识别出的肾素成分可能反映了利尿剂和血管扩张剂引起的肾素刺激,而β受体阻滞剂降低肾素的特性无法充分预防这种刺激。因此,卡托普利以及其他可能的特异性抗肾素药物,对于常规治疗难治的高血压患者可能是有价值的辅助治疗药物。